Amyotrophic Lateral Sclerosis (ALS) News and Research RSS Feed - Amyotrophic Lateral Sclerosis (ALS) News and Research

Amyotrophic lateral sclerosis in veterans: an interview with Milan Michael Karol, The Robert Packard Center for ALS Research at Johns Hopkins

Amyotrophic lateral sclerosis in veterans: an interview with Milan Michael Karol, The Robert Packard Center for ALS Research at Johns Hopkins

ALS stands for Amyotrophic Lateral Sclerosis, better known as “Lou Gehrig’s Disease”. It is a progressive neurodegenerative disease characterized by the death of motor neurons in the brain and spinal cord. [More]
ALS is aggravated by over-activity of HDAC6 enzyme, shows study

ALS is aggravated by over-activity of HDAC6 enzyme, shows study

Scientists at VIB and KU Leuven have demonstrated in fruit-flies that over-activity of the enzyme HDAC6 in the nerve ends exacerbates the symptoms of the neurodegenerative condition Amyotrophic Lateral Sclerosis (ALS / Lou Gehrig's Disease). Inhibition of this enzyme could offer a protective effect against ALS. [More]
Alternative disposal process in optic nerve cells has implications for neurodegenerative diseases

Alternative disposal process in optic nerve cells has implications for neurodegenerative diseases

Biologists have long considered cells to function like self-cleaning ovens, chewing up and recycling their own worn out parts as needed. [More]
Neurobiologist Thomas Jessell to be honored with 2014 Gruber Neuroscience Prize

Neurobiologist Thomas Jessell to be honored with 2014 Gruber Neuroscience Prize

Thomas Jessell, PhD, the Claire Tow Professor of Motor Neuron Disorders in the Departments of Neuroscience and of Biochemistry and Molecular Biophysics at Columbia University, is the recipient of the 2014 Neuroscience Prize of The Gruber Foundation. [More]
Researchers reveal potential new drug target for dementia

Researchers reveal potential new drug target for dementia

Researchers at King's College London have discovered how a molecular 'scaffold' which allows key parts of cells to interact, comes apart in dementia and motor neuron disease, revealing a potential new target for drug discovery. [More]
Pharmaceutical and academic leaders come together to discuss biomarkers in ALS

Pharmaceutical and academic leaders come together to discuss biomarkers in ALS

Leaders from academic institutions, non-profit organizations, and pharmaceutical companies will meet in Cambridge, Mass., on Monday, May 19, to discuss biomarkers in amyotrophic lateral sclerosis (ALS). [More]
UT Southwestern researchers identify potential new treatment for depression

UT Southwestern researchers identify potential new treatment for depression

Researchers at UT Southwestern Medical Center are making breakthroughs that could benefit people suffering from depression. [More]
Scientists uncover key mechanism that regulates nerve cell growth in damaged nervous system

Scientists uncover key mechanism that regulates nerve cell growth in damaged nervous system

New research published today out of the University of Calgary's Hotchkiss Brain Institute uncovers a mechanism to promote growth in damaged nerve cells as a means to restore connections after injury. Dr. Doug Zochodne and his team have discovered a key molecule that directly regulates nerve cell growth in the damaged nervous system. [More]
Study evaluates co-occurrence of cancers in patients with central nervous system disorders

Study evaluates co-occurrence of cancers in patients with central nervous system disorders

The study evaluated the co-occurrence of cancers in patients with central nervous system disorders, including Alzheimer's disease, amyotrophic lateral sclerosis, autism spectrum disorders, Down's syndrome, Huntington's disease, multiple sclerosis, Parkinson's disease and schizophrenia. [More]
Harvard stem cell scientists discover potential treatment for amyotrophic lateral sclerosis

Harvard stem cell scientists discover potential treatment for amyotrophic lateral sclerosis

Harvard stem cell scientists have discovered that a recently approved medication for epilepsy may possibly be a meaningful treatment for amyotrophic lateral sclerosis (ALS)-Lou Gehrig's disease, a uniformly fatal neurodegenerative disorder. The researchers are now collaborating with Massachusetts General Hospital to design an initial clinical trial testing the safety of the treatment in ALS patients. [More]
Endurance sport keeps both muscles and nerves fit

Endurance sport keeps both muscles and nerves fit

Endurance sport does not only change the condition and fitness of muscles but also simultaneously improves the neuronal connections to the muscle fibers based on a muscle-induced feedback. [More]
Human motor neurons can be quickly generated from stem cells, say researchers

Human motor neurons can be quickly generated from stem cells, say researchers

Researchers report they can generate human motor neurons from stem cells much more quickly and efficiently than previous methods allowed. The finding, described in Nature Communications, will aid efforts to model human motor neuron development, and to understand and treat spinal cord injuries and motor neuron diseases such as amyotrophic lateral sclerosis (ALS). [More]
Study points to potential culprit that kills motor neurons in ALS

Study points to potential culprit that kills motor neurons in ALS

Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, is marked by a cascade of cellular and inflammatory events that weakens and kills vital motor neurons in the brain and spinal cord. The process is complex, involving cells that ordinarily protect the neurons from harm. Now, a new study by scientists in The Research Institute at Nationwide Children's Hospital points to a potential culprit in this good-cell-gone-bad scenario, a key step toward the ultimate goal of developing a treatment. [More]
New way to make large concentrations of skeletal muscle cells from human stem cells

New way to make large concentrations of skeletal muscle cells from human stem cells

As stem cells continue their gradual transition from the lab to the clinic, a research group at the University of Wisconsin-Madison has discovered a new way to make large concentrations of skeletal muscle cells and muscle progenitors from human stem cells. [More]
Neuralstem announces results from Phase I trial using NSI-566 spinal cord stem cells in treatment of ALS

Neuralstem announces results from Phase I trial using NSI-566 spinal cord stem cells in treatment of ALS

Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were published in the peer-reviewed journal, "Annals of Neurology". [More]
Knopp and NIAID collaborate to investigate eosinophil-lowering effects of dexpramipexole

Knopp and NIAID collaborate to investigate eosinophil-lowering effects of dexpramipexole

Knopp Biosciences LLC today announced a second collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to investigate the eosinophil-lowering effects of the investigational drug dexpramipexole. [More]
New findings shed light on how gene mutation causes motor neurone disease

New findings shed light on how gene mutation causes motor neurone disease

Researchers have discovered a mechanism that may explain how a recently discovered mutation causes two devastating neurological diseases. [More]
New findings shed light on how gene mutation causes motor neurone disease

New findings shed light on how gene mutation causes motor neurone disease

Researchers have discovered a mechanism that may explain how a recently discovered mutation causes two devastating neurological diseases. [More]
Scientists reveal how a genetic code variation results in devastating brain diseases

Scientists reveal how a genetic code variation results in devastating brain diseases

New findings reveal how a mutation, a change in the genetic code that causes neurodegeneration, alters the shape of DNA, making cells more vulnerable to stress and more likely to die. [More]
Genervon's GM604 bio-drug receives FDA orphan drug designation for ALS treatment

Genervon's GM604 bio-drug receives FDA orphan drug designation for ALS treatment

Genervon Biopharmaceuticals announced today that the U.S. Food and Drug Administration has granted an "orphan drug" designation to Genervon's GM604 (a.k.a. GM6) bio-drug for the treatment of Amyotrophic Lateral Sclerosis (ALS). The FDA also granted GM604 a "fast-track" designation for ALS in 2013. [More]